A population-based comparison of patients with metastatic esophagogastric carcinoma between Japan and the Netherlands.

[1]  Japanese Gastric Cancer Association.  Japanese Gastric Cancer Treatment Guidelines 2021 (6th edition) , 2022, Gastric Cancer.

[2]  R. van Hillegersberg,et al.  Liver oligometastatic disease in synchronous metastatic gastric cancer patients: a nationwide population-based cohort study. , 2022, European journal of cancer.

[3]  T. Leong,et al.  Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. Lordick,et al.  Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. , 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  Zeyang Chen,et al.  Comparison of Treatment Efficacy and Survival Outcomes Between Asian and Western Patients With Unresectable Gastric or Gastro-Esophageal Adenocarcinoma: A Systematic Review and Meta-Analysis , 2022, Frontiers in Oncology.

[6]  K. Katanoda,et al.  Is young‐onset esophageal adenocarcinoma increasing in Japan? An analysis of population‐based cancer registries , 2022, Cancer medicine.

[7]  N. Boku,et al.  Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study , 2021, Advances in Therapy.

[8]  R. Verhoeven,et al.  The metastatic pattern of intestinal and diffuse type gastric carcinoma - A Dutch national cohort study. , 2020, Cancer epidemiology.

[9]  M. Szklo,et al.  The diffuse-type gastric cancer epidemiology enigma , 2020, BMC Gastroenterology.

[10]  J. Ferlay,et al.  Global burden of oesophageal and gastric cancer by histology and subsite in 2018 , 2020, Gut.

[11]  Yasuhide Yamada,et al.  Present status and perspective of chemotherapy for patients with unresectable advanced or metastatic gastric cancer in Japan. , 2020, Global health & medicine.

[12]  V. Lemmens,et al.  A population-based study on intestinal and diffuse type adenocarcinoma of the oesophagus and stomach in the Netherlands between 1989 and 2015. , 2020, European journal of cancer.

[13]  P. Siersema,et al.  Long-term survival improvement in oesophageal cancer in the Netherlands. , 2018, European journal of cancer.

[14]  Ken Kato,et al.  A retrospective analysis of 5-fluorouracil plus cisplatin as first-line chemotherapy in the recent treatment strategy for patients with metastatic or recurrent esophageal squamous cell carcinoma , 2018, International Journal of Clinical Oncology.

[15]  S. Ng,et al.  Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. , 2017, Gastroenterology.

[16]  S. Barni,et al.  Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. , 2017, Journal of gastrointestinal oncology.

[17]  Japan Esophageal Society.  Japanese Classification of Esophageal Cancer, 11th Edition: part I , 2016, Esophagus.

[18]  M. V. van Oijen,et al.  The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis. , 2016, Journal of the National Cancer Institute.

[19]  I. Chau,et al.  Variations in outcome for advanced gastric cancer between Japanese and Western patients: a subgroup analysis of the RAINBOW trial. , 2016, Translational gastroenterology and hepatology.

[20]  M. V. van Oijen,et al.  The efficacy and safety of S-1-based regimens in the first-line treatment of advanced gastric cancer: a systematic review and meta-analysis , 2016, Gastric Cancer.

[21]  Ying Cheng,et al.  A phase III study of S-1 plus cisplatin versus fluorouracil plus cisplatin in patients with advanced gastric or gastroesophageal junction adenocarcinoma. , 2013 .

[22]  L. Shen,et al.  Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study , 2008 .

[23]  T. Ohkusa,et al.  Detection of Helicobacter pylori infection in early stage gastric cancer. A comparison between intestinal‐ and diffuse‐type gastric adenocarcinomas , 1995, Cancer.

[24]  J. Parsonnet,et al.  Helicobacter pylori infection in intestinal- and diffuse-type gastric adenocarcinomas. , 1991, Journal of the National Cancer Institute.

[25]  E. Baba,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  Jun Yu Li,et al.  Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  K Nishikawa,et al.  Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.